Literature DB >> 7623658

Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis.

T M Wilson1, G W de Lisle, D M Collins.   

Abstract

Isoniazid (INH) resistance of the Mycobacterium tuberculosis Complex (MtbC) is associated with both loss of catalase activity and mutation of the inhA gene. However, the relative contributions of these changes to resistance and to the loss of virulence for guinea-pigs is unknown. In this study, a virulent strain of Mycobacterium bovis, a member of the MtbC, was exposed to increasing concentrations of INH. Two INH-resistant strains were produced which had lost catalase activity. Strain WAg405, which had a higher resistance to INH, also had a mutation in the inhA gene. This demonstrated that loss of catalase activity and mutation of inhA had a cumulative effect on INH resistance. When a functional katG gene was integrated into the genome of WAg405 the INH resistance was greatly reduced. This indicated that most of the resistance had been caused by loss of catalase activity. While the parent INH-sensitive strain was virulent for guinea-pigs, the INH-resistant strains were significantly less virulent. Integration of a functional katG gene into the most resistant strain restored full virulence. This clearly established that katG is a virulence factor for M. bovis and that mutation of the inhA gene has no effect on virulence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623658     DOI: 10.1111/j.1365-2958.1995.tb02276.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  43 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis.

Authors:  G W De Lisle; T Wilson; D M Collins; B M Buddle
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 4.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

5.  Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis.

Authors:  B Saint-Joanis; H Souchon; M Wilming; K Johnsson; P M Alzari; S T Cole
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

Review 6.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

7.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

8.  Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro.

Authors:  C Manca; S Paul; C E Barry; V H Freedman; G Kaplan
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 9.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

10.  The multifunctional histone-like protein Lsr2 protects mycobacteria against reactive oxygen intermediates.

Authors:  R Colangeli; A Haq; V L Arcus; E Summers; R S Magliozzo; A McBride; A K Mitra; M Radjainia; A Khajo; W R Jacobs; P Salgame; D Alland
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.